QuidelOrtho Reports In-Line Q4/FY25 Results, Projects Strong FY26 Growth & Free Cash Flow Turnaround
QDEL sits 48% above its 52-week low of $19.5.
Summary
QuidelOrtho reported Q4 and full-year 2025 results that met guidance for key non-GAAP metrics, while also providing strong fiscal year 2026 guidance, including a significant projected improvement in free cash flow. The company also announced the planned retirement of its CFO.
Key Events · Earnings and Guidance · QDEL
-
Q4 and Full-Year 2025 Financial Results
QuidelOrtho reported full-year 2025 total revenue of $2.73 billion, adjusted EBITDA of $597 million, and adjusted diluted EPS of $2.12, all within previously issued guidance ranges. The company recorded a GAAP net loss of $1.13 billion, which included a $701 million non-cash goodwill impairment charge. Free cash flow for FY25 was negative $77 million, impacted by one-time ERP system conversion investments.
-
Strong FY2026 Financial Guidance
The company provided fiscal year 2026 guidance, projecting total revenues between $2.7 billion and $2.9 billion, adjusted EBITDA of $630 million to $670 million, and adjusted diluted EPS of $2.00 to $2.42. Notably, free cash flow is expected to significantly improve to $120 million to $160 million, marking a substantial turnaround from the prior year.
-
CFO Joseph M. Busky to Retire
Joseph M. Busky, Chief Financial Officer, announced his decision to retire effective June 30, 2026. The company has initiated a search for his successor, and Mr. Busky will serve in an advisory role to ensure a smooth transition.
Analysis · QDEL · Life Sciences
QuidelOrtho Corp announced financial results for Q4 and full-year 2025, meeting its guidance for key non-GAAP metrics such as total revenue, adjusted EBITDA, and adjusted diluted EPS. While the company reported a significant GAAP net loss for the full year, this included a substantial non-cash goodwill impairment charge. More importantly, the company provided robust financial guidance for fiscal year 2026, projecting growth in total revenues, adjusted EBITDA, and a significant turnaround in free cash flow from a negative $77 million in FY25 to a positive $120-$160 million. This strong forward-looking guidance, particularly the free cash flow improvement, signals a healthier financial trajectory for the company. Additionally, the company announced the planned retirement of its CFO, Joseph M. Busky, effective June 30, 2026, with a search for a successor underway and a smooth transition planned.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QDEL was trading at $28.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $19.50 to $43.92. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.